Erasca, Inc. filings document a clinical-stage oncology issuer focused on RAS/MAPK pathway-driven cancers and common stock listed on the Nasdaq Global Select Market. Recent Form 8-K reports disclose ERAS-0015 clinical data from AURORAS-1 and JYP0015M101, Regulation FD materials, financial results, cash and marketable-securities information, and common-stock offering activity under a shelf registration statement.
Proxy materials cover annual meeting procedures, director elections, executive compensation, and stockholder voting matters. Other event reports record intellectual-property correspondence involving ERAS-0015 and provide formal updates on the company's pipeline, capital structure, and public-company governance.
Erasca, Inc. reported interim Phase 1 results for ERAS-0015. At the September 1, 2026 cutoff, confirmed ORR was 44% in 25 KRAS G12X PDAC patients at 32 mg once daily in second line or later, and 69% in 13 patients with KRAS G12D or G12V PDAC. Confirmed ORR was 58% in 12 KRAS G12X NSCLC patients across 16–32 mg and 75% in four biliary tract cancer patients at 32 mg.
At 32 mg, TRAEs caused dose interruptions in 13.0% and reductions in 16.7% of 54 patients, with no discontinuations. One previously reported pneumonitis TRAE progressed from Grade 3 to Grade 5 after the patient requested withdrawal of supportive care; no further Grade 5 TRAEs occurred. Combination escalation showed multiple responses with pembrolizumab and panitumumab; gemcitabine/nab-paclitaxel efficacy data were not yet available. Preliminary ERAS-4001 data showed no TRAEs leading to discontinuation.
First-line PDAC Phase 3 and potentially registration-enabling second-line-or-later RAS-mutant NSCLC trials are expected to start in the first half of 2027. First-line RAS-mutant NSCLC Phase 3 is expected in the second half of 2027 to the first half of 2028; an ERAS-0015/ERAS-4001 combination dose-escalation trial is planned for 2027.
Erasca, Inc. (ERAS) is the issuer named in Erasca Foundation’s notice of a proposed sale of 8,333 common shares, with an approximate market value of $129,255.86 and approximate sale date of November 16, 2026. The foundation acquired 1,093,557 shares by donation from Erasca, Inc. on July 20, 2021. The notice lists May 21, 2026 as the plan-adoption or instruction date if relying on Rule 10b5-1.
Erasca, Inc. is the issuer in an amended ownership report in which T. Rowe Price Investment Management, Inc. reported 17,212,014 common shares, or 4.9% of the class, for September 30, 2026. The firm stated that the report should not be construed as an admission of beneficial ownership and expressly denied that status. Ellen York, Vice President, signed for the reporting person.
Erasca, Inc. (ERAS) is covered by an amended beneficial-ownership report from RTW Investments, LP, an investment adviser to certain funds, and Roderick Wong, M.D., RTW Investments’ Managing Partner and Chief Investment Officer. Each reports beneficial ownership of 22,446,754 shares, or 6.4%, with shared voting and dispositive power; the shares are directly held by the RTW Funds. The reported percentage is calculated using 349,762,035 shares outstanding as of August 4, 2026. The statement says it is not an admission that either reporting person is a beneficial owner for Section 13 purposes.
Erasca, Inc. reported a net loss of $51.3 million, or $(0.15) per share, for the quarter ended September 30, 2026, compared with $30.6 million, or $(0.11) per share, for the quarter ended September 30, 2025. Research and development expenses were $47.2 million versus $22.5 million, and general and administrative expenses were $12.3 million versus $10.1 million. Cash, cash equivalents and marketable securities were $947.8 million as of September 30, 2026, compared with $341.8 million as of December 31, 2025; Erasca expects its current balance to fund the listed milestones. It completed an upsized public offering in July 2026 that raised approximately $632.5 million in gross proceeds.
In August 2026, the FDA granted ERAS-0015 Fast Track Designation for metastatic pancreatic adenocarcinoma. Erasca expects Phase 1 monotherapy expansion and combination dose-escalation data in the first half of 2027, and expects to initiate a potentially registration-enabling trial in second line or greater NSCLC in the first half of 2027. A Phase 3 pivotal trial in first-line PDAC is expected to initiate in 2027; preliminary ERAS-4001 monotherapy data are expected in the second half of 2026.
Erasca, Inc. (ERAS), a clinical-stage oncology company, reported a third-quarter 2026 net loss of $51.3 million, versus $30.6 million a year earlier; its nine-month loss was $278.9 million, versus $95.5 million. Nine-month research and development expense was $110.4 million, versus $69.6 million, including $150.0 million in in-process research and development expense. A July underwritten offering of 36,142,857 shares at $17.50 generated $593.5 million net. At September 30, 2026, Erasca held $947.8 million in cash, cash equivalents and marketable securities; management believes this will fund operations for at least one year from the statements’ issuance date.
Erasca is advancing ERAS-0015 and ERAS-4001 in clinical trials; the FDA granted ERAS-0015 Fast Track Designation for metastatic pancreatic adenocarcinoma. Preliminary AURORAS-1 data reported a 57% uORR8wk at 32 mg once daily among seven second-line-or-later KRAS G12X pancreatic cancer patients as of May 25, 2026. One treatment-related pneumonitis event progressed to Grade 5 after withdrawal of supportive care, and the patient died. Erasca plans to seek a partner for ERAS-12 and stopped naporafenib development; its license termination took effect June 3, 2026.
On October 15, 2026, Erasca, Inc. decided to realign leadership responsibilities to support development and potential commercialization of its RAS-targeting programs. Responsibilities currently overseen by Chief Operating Officer Nicholas (Nik) Chetwyn, Ph.D., are transitioning to other members of the leadership team to streamline the reporting structure. His employment will terminate effective November 2, 2026.
Erasca, Inc. (ERAS) identifies Erasca Foundation as the account for a proposed sale of 8,333 common shares, with an aggregate market value of $122,353.03 and an approximate sale date of October 15, 2026, through Merrill Lynch. The notice lists three prior foundation sales of 8,333 shares each, dated September 15, August 17 and July 21, 2026.
Erasca, Inc. (ERAS) has a notice that Erasca Foundation intends to sell common stock under Rule 144. The Foundation plans to sell 8,333 shares$133,093.91
The filing also lists prior sales by Erasca Foundation over the past three months and discloses that the Foundation originally acquired 10,193,557 shares
Erasca, Inc. (ERAS) reports that the U.S. Food and Drug Administration has granted Fast Track Designation (FTD) to its product candidate ERAS-0015 for treating patients with metastatic pancreatic adenocarcinoma. FTD is intended to facilitate development and expedite review of therapies for serious conditions with unmet medical needs through more frequent FDA interactions and potential access to accelerated approval, priority review, and rolling review if relevant criteria are met.
Erasca notes that FTD does not change approval standards and may not shorten review time or increase the likelihood of marketing approval. The company highlights plans involving ERAS-0015, including a potential phase 3 trial in pancreatic cancer and two potentially registration-enabling trials in lung cancer, while emphasizing significant clinical, regulatory, and safety risks and uncertainties.